<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Effects of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> (<z:chebi fb="0" ids="15627">TXA2</z:chebi>) synthase inhibitors (CV-4151 and ozagrel) on <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> and cerebral damage were examined in a rat middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) <z:mp ids='MP_0005048'>thrombosis</z:mp> model and their potencies were compared with the conventional antithrombotic agents, aspirin and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>CV-4151 significantly inhibited photochemically induced <z:chebi fb="70" ids="34342">MCA</z:chebi> <z:mp ids='MP_0005048'>thrombosis</z:mp> by oral (1 and 10 mg/kg) and intravenous (1 mg/kg) administration </plain></SENT>
<SENT sid="2" pm="."><plain>Ozagrel (10 mg/kg, p.o.) also inhibited it </plain></SENT>
<SENT sid="3" pm="."><plain>The potency of CV-4151 was about 10 times stronger than that of ozagrel, being comparable with the inhibition of blood <z:chebi fb="0" ids="15627">TXA2</z:chebi> generation </plain></SENT>
<SENT sid="4" pm="."><plain>Aspirin (100 mg/kg, p.o.) and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> (300 mg/kg, p.o.) showed an inhibitory tendency on <z:chebi fb="70" ids="34342">MCA</z:chebi> <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-four h after photochemical stimulation, <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> and <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> were observed, and the <z:chebi fb="4" ids="24996">lactate</z:chebi> content in the brain increased </plain></SENT>
<SENT sid="6" pm="."><plain>CV-4151 and ozagrel prevented this <z:hpo ids='HP_0000969'>edema</z:hpo>, and the antiedema effects of the drugs were correlated with the antithrombotic effect on thrombotic <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="7" pm="."><plain>CV-4151 (10 mg/kg, p.o.), furthermore, significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size and inhibited the increase in <z:chebi fb="4" ids="24996">lactate</z:chebi> content </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate that <z:chebi fb="0" ids="15627">TXA2</z:chebi> synthase inhibitors inhibit cerebral damage by inhibition of <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion with <z:mp ids='MP_0005048'>thrombosis</z:mp>, probably resulting from the inhibition of <z:chebi fb="0" ids="15627">TXA2</z:chebi> generation, and their effects are superior to those of aspirin and <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="15627">TXA2</z:chebi> might play an important role in cerebral damage in the <z:chebi fb="70" ids="34342">MCA</z:chebi> <z:mp ids='MP_0005048'>thrombosis</z:mp> model </plain></SENT>
<SENT sid="10" pm="."><plain>CV-4151 might be a useful drug for the treatment of <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> and for the prevention of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
</text></document>